The ASTCT Pharmacy SIG March 2025 Journal Club will air on Wednesday, March 26 at 2 pm CT/3 pm ET.

This educational offering will focus on core topics in hematopoietic cell transplantation (HCT) and cellular therapy. The target audience is PGY2 Oncology Pharmacy Residents, but participation is open to all pharmacists or pharmacy trainees practicing or interested in transplantation and cellular therapy.

The Pharmacy HCT Core Topics Connection Live Session will air on Tuesday, November 12, at 2 p.m. CT/3 p.m. ET.

Join our expert panelists in this roundtable webinar in recognition the inaugural GVHD Day on Friday, February 17, to discuss unmet needs in graft-versus-host disease (GVHD).

Join Dr. Kirk R. Schultz from the University of British Columbia as he discusses new and emerging therapies in cGvHD. In this 20 min. presentation, he focuses on the future directions of treatment for cGvHD, including the idea of synergistic therapy and how biomarkers may be used to personalize therapy.

Join Olaf Penack, MD from the Charité Universitätsmedizin Berlin, Germany as he reviews the management of cGVHD. In this 20 minute presentation, he focuses on prevention strategies for infectious and non-infectious complications of the disease and discusses current gaps that future research may fill.

In this 20 minute module, Dr. Kirsten Williams from Children’s Healthcare of Atlanta reviews the most recent NIH consensus statements on diagnosis, staging, and response scoring of chronic graft-versus-host disease after hematopoietic stem cell transplant. The current focus in this area is early detection. This is a first in a series of three modules addressing unmet needs in chronic graft versus host disease.

This package includes all 12 recordings of the ASTCT Education Sessions that were aired live during the 2021 TCT Meetings of ASTCT & CIBMTR.

This session aired as an ASTCT Education Session during the 2021 TCT Meetings of ASTCT & CIBMTR.

This session aired as an ASTCT Education Session during the 2021 TCT Meetings of ASTCT & CIBMTR.